Bruera, G., Cannita, K., Di Giacomo, D., Lamy, A., Troncone, G., Dal Mas, A., . . . Ricevuto, E. (2012). Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease. BioMed Central.
Čikaški stil citiranjaBruera, Gemma, et al. Prognostic Value of KRAS Genotype in Metastatic Colorectal Cancer (MCRC) Patients Treated With Intensive Triplet Chemotherapy Plus Bevacizumab (FIr-B/FOx) According to Extension of Metastatic Disease. BioMed Central, 2012.
MLA način citiranjaBruera, Gemma, et al. Prognostic Value of KRAS Genotype in Metastatic Colorectal Cancer (MCRC) Patients Treated With Intensive Triplet Chemotherapy Plus Bevacizumab (FIr-B/FOx) According to Extension of Metastatic Disease. BioMed Central, 2012.